The US Food and Drug Administration approved Libtayo (cemiplimab-rwlc) on 28 September for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) who are not eligible for curative surgery or radiation. The approval is the FDA’s first authorisation of a drug specifically for an advanced form of this disease.
